Related Experiment Video
Updated: Jun 14, 2025
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Targeting non-histone methylation in gastrointestinal cancers: From biology to clinic
Zhanbo Sun1, Lixian Liu2, Jun Chen3
1Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, 110004, PR China.
Abstract:
Gastrointestinal (GI) cancers, encompassing a range of malignancies within the digestive tract, present significant challenges in both diagnosis and treatment, reflecting a dire need for innovative therapeutic strategies. This article delves into the profound influence of non-histone methylation on the pathogenesis and evolution of gastrointestinal (GI) cancers. Non-histone proteins, undergoing methylation by enzymes such as Protein Arginine Methyltransferases (PRMTs) and Lysine Methyltransferases (KMTs), play pivotal roles in cellular signaling, metabolism, chromatin remodeling, and other processes crucial for cancer development. This review illuminates the complex mechanisms by which non-histone methylation affects key aspects of tumor biology, including oncogenesis, growth, proliferation, invasion, migration, metabolic reprogramming, and immune escape in GI malignancies. Highlighting recent discoveries, this work underscores the importance of non-histone methylation in cancer biology and its potential as a target for innovative therapeutic strategies aimed at improving outcomes for patients with GI cancers.
Insights
Non-histone methylation significantly impacts gastrointestinal (GI) cancer development and progression. Targeting these methylation processes offers promising new therapeutic strategies for GI malignancies.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Gastrointestinal (GI) cancers pose significant diagnostic and therapeutic challenges.
- Innovative strategies are urgently needed to combat these malignancies.
- Non-histone methylation is increasingly recognized as a critical factor in cancer.
Purpose of the Study:
- To review the role of non-histone methylation in the pathogenesis and evolution of GI cancers.
- To elucidate the mechanisms by which non-histone methylation influences tumor biology.
- To highlight the therapeutic potential of targeting non-histone methylation in GI malignancies.
Main Methods:
- Literature review focusing on non-histone methylation in GI cancer.
- Analysis of enzymatic pathways involving Protein Arginine Methyltransferases (PRMTs) and Lysine Methyltransferases (KMTs).
- Examination of non-histone methylation's impact on oncogenesis, metabolism, and immune response.
Main Results:
- Non-histone methylation regulates key cellular processes including signaling, metabolism, and chromatin remodeling.
- Aberrant methylation is implicated in oncogenesis, proliferation, invasion, and migration of GI cancer cells.
- Non-histone methylation influences metabolic reprogramming and immune evasion in GI tumors.
Conclusions:
- Non-histone methylation is a crucial driver in the development and progression of GI cancers.
- Understanding these mechanisms is vital for developing novel therapeutic approaches.
- Targeting non-histone methylation pathways presents a promising avenue for improving patient outcomes in GI oncology.
Related Concept Videos
01:37Epigenetic Regulation
X-chromosome...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...